PMN310 for Alzheimer's Disease
Trial Summary
Will I have to stop taking my current medications?
The trial allows patients to continue taking FDA-approved acetylcholinesterase inhibitors or memantine as long as the dose has been stable for at least 3 months before screening. However, if you are currently receiving anti-amyloid treatments, you must stop them at least 9 months before screening.
What data supports the effectiveness of the drug PMN310 for Alzheimer's Disease?
How does the drug PMN310 for Alzheimer's disease differ from other treatments?
What is the purpose of this trial?
This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.
Eligibility Criteria
This trial is for individuals with early Alzheimer's disease. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be required to have a particular stage or severity of Alzheimer's.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive PMN310 or placebo once every 28 days for a total of 12 infusions
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PMN310
Find a Clinic Near You
Who Is Running the Clinical Trial?
ProMis Neurosciences, Inc
Lead Sponsor